Summary

The 7 major thyroid cancer markets reached a value of US$ 303.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,624.3 Million by 2034, exhibiting a growth rate (CAGR) of 16.49% during 2024-2034.

The thyroid cancer market has been comprehensively analyzed in IMARC's new report titled "Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Thyroid cancer is a type of endocrine cancer that affects the thyroid gland, a small butterfly-shaped gland located in the front base of the neck that produces metabolism-regulating hormones. This disease occurs when cells in the thyroid gland grow abnormally and uncontrollably, forming a tumor. The ailment is classified into several types, including papillary, follicular, medullary, and anaplastic. Papillary thyroid cancer is the most general type and tends to grow slowly, while anaplastic thyroid cancer is the rarest and most aggressive form. The common symptoms of thyroid cancer include a lump or swelling in the neck, hoarseness, difficulty speaking, shortness of breath, trouble swallowing, pain in the neck or throat, a persistent cough, swollen lymph nodes in the neck, etc. The diagnosis of the illness is based on a review of the patient's medical history, underlying indications, and a physical exam. The healthcare provider may also perform several diagnostic tests and procedures, such as ultrasound imaging, CT scans, MRI, genetic testing, fine-needle aspiration biopsy, thyroid function blood workups, etc., to confirm the disease.

The increasing cases of inherited genetic syndromes, which lead to DNA mutations, causing cells to grow and multiply abnormally, are primarily driving the thyroid cancer market. In addition to this, the rising prevalence of various associated risk factors, including radiation exposure, consumption of a low-iodine diet, a family history of thyroid disease, obesity, etc., is also bolstering the market growth. Moreover, the inflating utilization of radioactive iodine therapy, which shrinks and disrupts the diseased thyroid gland, is further creating a positive outlook for the market. Apart from this, the widespread adoption of thyroidectomy followed by hormone replacement therapy for treating the condition on account of their numerous advantages, such as inhibition of tumor growth, reduced risk of refractory cancer, and maintenance of normal metabolism, is also augmenting the market growth. Additionally, several technological advancements in the field of radiation therapy, including the launch of stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT), are enhancing treatment outcomes in patients while minimizing toxic effects. This, in turn, is further expected to drive the thyroid cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the thyroid cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for thyroid cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the thyroid cancer market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the thyroid cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the thyroid cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current thyroid cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the thyroid cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the thyroid cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the thyroid cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of thyroid cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of thyroid cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of thyroid cancer by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of thyroid cancer by type across the seven major markets?
How many patients are diagnosed (2018-2034) with thyroid cancer across the seven major markets?
What is the size of the thyroid cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of thyroid cancer?
What will be the growth rate of patients across the seven major markets?

Thyroid Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for thyroid cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the thyroid cancer market?
What are the key regulatory events related to the thyroid cancer market?
What is the structure of clinical trial landscape by status related to the thyroid cancer market?
What is the structure of clinical trial landscape by phase related to the thyroid cancer market?
What is the structure of clinical trial landscape by route of administration related to the thyroid cancer market?

ページTOPに戻る

Table of Contents

​1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Thyroid Cancer - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Thyroid Cancer - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Thyroid Cancer - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)

8 Thyroid Cancer - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Thyroid Cancer - Unmet Needs

10 Thyroid Cancer - Key Endpoints of Treatment

11 Thyroid Cancer - Marketed Products
11.1 List of Thyroid Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Retevmo (Selpercatinib) - Loxo oncology
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Nexavar (Sorafenib) - Bayer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gavreto (Pralsetinib) - Blueprint Medicines/Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Thyroid Cancer - Pipeline Drugs
12.1 List of Thyroid Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Binimetinib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MLN0128 - Takeda Oncology
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pembrolizumab - Merck & Co
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Surufatinib - HUTCHMED
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Thyroid Cancer - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Thyroid Cancer – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Thyroid Cancer - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Thyroid Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Thyroid Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Thyroid Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Thyroid Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Thyroid Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Thyroid Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Thyroid Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Thyroid Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Thyroid Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Thyroid Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Thyroid Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Thyroid Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Thyroid Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Thyroid Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Thyroid Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Thyroid Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Thyroid Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Thyroid Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Thyroid Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Thyroid Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Thyroid Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Thyroid Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Thyroid Cancer - Access and Reimbursement Overview

16 Thyroid Cancer - Recent Events and Inputs From Key Opinion Leaders

17 Thyroid Cancer Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Thyroid Cancer Market – Strategic Recommendations

19 Appendix